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Background: Colistin has become a last-resort antibiotic for the management of multidrug-
resistant gram-negative bacteria. The disk diffusion test is cheap and easy to perform but 
may be unreliable for colistin susceptibility testing due to poor diffusion of the large colistin 
molecule. An improved agar diffusion test would increase the reliability of colistin suscep-
tibility testing. This study aimed to modify Muller-Hinton agar (MHA) to improve colistin 
diffusion in agar. 
Methods: MHA was modified by reducing the agar concentration from 100% to 30% and 
supplementing with protamine. We tested 60 gram-negative clinical isolates of Pseudomo-
nas aeruginosa (N=27) and Acinetobacter calcoaceticus-baumannii complex (N=33). 
Disk diffusion test results were interpreted based on minimum inhibitory concentrations 
determined by broth microdilution. 
Results: The modified MHA yielded the best performance metrics, including 94.7% sen-
sitivity, 100% specificity, and an area under the curve of 0.995 (95% confidence interval, 
0.982–1.000), P <0.001, at a cut-off point of 13 mm. 
Conclusions: A reduction of the agar concentration from 100% to 30% and the addition 
of protamine improved colistin diffusion in agar and allowed routine colistin susceptibility 
testing in a clinical microbiology laboratory, but should be handled with caution. 
Key Words: Colistin, Disk diffusion, Colistin susceptibility testing, Muller-Hinton agar, Prot-
amine
Received: June 3, 2019
Revision received: October 8, 2019
Accepted: February 7, 2020
Corresponding author:  
Jung-Hyun Byun, M.D.
Department of Laboratory Medicine, 
Gyeongsang National University Hospital, 
Gyeongsang National University College of 





Dongeun Yong, M.D., Ph.D. 
Department of Laboratory Medicine and 
Research Institute of Bacterial Resistance, 
Yonsei University College of Medicine,  





© Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (https://creativecom-
mons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
INTRODUCTION
With limited new antibiotic classes in the drug development 
pipeline, the global challenge of antimicrobial resistance, partic-
ularly in the treatment of multidrug-resistant (MDR) gram-nega-
tive (GN) bacteria, remains critical. Colistin, also known as poly-
myxin E, has become a last-resort antibiotic for the manage-
ment of MDR GN bacteria [1, 2]. Colistin, a member of an old 
class of cationic, cyclic, polypeptide antibiotics was first intro-
duced in Japan in 1947 from the soil bacterium Paenibacillus 
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polymyxa and adopted for clinical use in 1959 [3]. 
Although its use was abandoned in the 1980s because of 
concerns of nephrotoxicity and neurotoxicity [4], intravenous in-
jection of colistin sulfate was demonstrated to be safe and could 
be considered for the management of severe infections from 
sensitive MDR GN pathogens [5]. Therefore, beginning in the 
mid-1990s, the clinical use of polymyxins was revived, with a 
focus on colistin because of its rapid bactericidal effect, broad-
spectrum activity against MDR GN pathogens, and the lack of 
novel antibiotics against the most prevalent MDR GN bacteria 
[3, 5-10]. The global colistin resistance rate is less than 10%, 
but is increasing. Increased resistance has been reported in 
Mediterranean and Southeast Asian countries [11]. 
The increasing use of colistin over the past several years has 
necessitated rapid, accurate, and reliable in-vitro antimicrobial 
susceptibility testing (AST) methods to allow appropriate thera-
peutic decisions. The disk diffusion test, commonly used in clini-
cal laboratories, is considered to be unreliable because colistin 
diffuses poorly into agar due to electrostatic interactions with acid 
or sulfate groups of agar, resulting in smaller inhibition zones 
[12]. The poor diffusion results in high error rates compared to 
the broth microdilution (BMD) test for minimum inhibitory con-
centration (MIC) determination [13]. Other methods, such as 
the VITEK 2 AST system (bioMérieux, Marcy l’Etoile, France), E-
test (AB Biodisk, Solna, Sweden), and agar dilution, also remain 
unreliable [14-19]. There is currently no standardized disk dif-
fusion test for colistin susceptibility testing for use in clinical mi-
crobiology laboratories [20]. 
This study aimed to develop a simple disk diffusion test method 
for colistin susceptibility testing by modifying the commercial 
Mueller-Hinton medium to improve colistin diffusion in agar. 
MATERIALS AND METHODS
Phase I
Disk diffusion test 
The colistin disk diffusion test was performed using a 10 mg co-
listin disk on Mueller-Hinton agar (MHA) plates that were incu-
bated at 35°C for 16–18 hours in 5% CO2. Disk diffusion test 
results were interpreted based on the diameter of inhibition zone 
and compared with MICs determined by BMD according to the 
2018 CLSI guidelines [21].
Optimization of the agar concentration 
First, an optimum agar concentration was determined using four 
strains: P. aeruginosa ATCC 27853, a colistin-susceptible Aci-
netobacter calcoaceticus-baumannii complex (ACB) strain, a 
colistin-resistant ACB strain, and mcr-1-harboring Klebsiella aero-
genes. Assays were run in triplicate. Species were identified us-
ing a Microflex LT Biotyper (Bruker Daltonics, Leipzig, Germany). 
MHA was modified by reducing the agar granule concentration 
from 100% (17 g/L) to 30% (5.1 g/L) of the concentration in com-
mercial MHA with 10% intervals (Becton, Dickinson, & Com-
pany, Sparks, MD, USA). The optimum concentration was de-
termined based on the least agar concentration that was man-
ageable in the laboratory. Lower the agar concentration, more 
fragile is the AST determination. The final agar concentration 
was reduced to 30%.
Optimization of the protamine concentration 
We added protamine (Sigma-Aldrich, St Louis, MO, USA) to the 
modified MHA at various concentrations (1,000 μg/mL, 700 μg/
mL, 400 μg/mL, 300 μg/mL, 200 μg/mL, 150 μg/mL, 100 μg/
mL, and 50 μg/mL) to determine an optimal concentration that 
would promote colistin diffusion in agar, but not inhibit bacterial 
growth. Protamine was measured, mixed with distilled water un-
til completely dissolved, and then added to the MHA before au-
toclaving.
Phase II 
Colistin MIC and inhibition zone diameter around colistin disks on 
modified MHA
In total, 60 GN clinical isolates obtained from Severance hospi-
tal, including P. aeruginosa (N=27) and ACB (N=33), were 
tested (Table 1). The study was approved by the Institutional 
Review Board of Yonsei University Health system, Seoul, Korea. 
(1-2017-0079). The clinical strains were collected from sputum 
and urine in 2017 and stored at -70°C.
Quality control was performed using E. coli (ATCC 25922), P. 
aeruginosa (ATCC 27853), and mcr-1-harboring K. aerogenes (a 
clinical isolate). Colistin MICs were determined by BMD for all 
60 strains using colistin sulfate salt (Sigma-Aldrich, St. Louis, 
MO, USA) and polystyrene 96-well microplates (Corning, NY, 
USA). As shown in Table 1, disk diffusion AST results were in-
terpreted based on the breakpoints, which showed good agree-
ment with the MIC determined by BMD according to the 2018 
CLSI guidelines [21]. Each strain was tested using predetermined 
media, i.e., commercial MHA (100% agar concentration), MHA 
with 30% agar (MHA30), and MHA30 with 100 μg/mL prot-
amine (MHA30P100), which were selected based on the opti-
mization in phase I. The colistin disk diffusion test was performed 
using a 10 mg colistin disk on MHA plates that were incubated 
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Table 1. Comparison between colistin MICs and inhibition zone diameters for P. aeruginosa and ACB complex
Inhibition zone diameter (mm) with:
P. aeruginosa isolates with colistin MIC (µg/mL) (N) ACB isolates with colistin MIC (µg/mL) (N)
Susceptible Resistant Susceptible Resistant
1 2 4 8 1 2 4 8
MHA




10 2 1 1
   Susceptible 11 1 10 1 12 1















   Susceptible 13 3
14 1 5 1 10 1













   Susceptible 14
15 1 7 1
16 2 7 1 8
17 11
18 3 1
Abbreviations: ACB, Acinetobacter calcoaceticus-baumannii complex; MHA, Mueller-Hinton agar with 100% agar concentration; MHA30, MHA with 30% 
agar concentration; MHA30P100, MHA30 with 100 μg/mL protamine; MIC, minimum inhibitory concentration; R, resistance; S, Susceptible.
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at 35°C for 16–18 hours in 5% CO2. 
Statistical analysis 
Descriptive and statistical analyses were performed using SPSS 
21 (Armonk, NY, USA) and MedCalc Statistical Software 18.10 
(MedCalc Software, Ostend, Belgium; http://www.medcalc.org). 
Colistin MICs, as reference test, and disk diffusion results were 
compared to calculate sensitivity, specificity, and Kappa value of 
this simple disk diffusion test. Area under the curve (AUC) for 
inhibition zone diameters cutoff was determined from the re-




Colistin diffusion was optimized using MHA30, because we could 
not use the MHA with 20% or 10% agar (data not shown). At 
30% agar concentration, the addition of protamine inhibited 
bacterial growth and enhanced colistin diffusion. Colistin diffu-
sion in the agar improved with protamine supplementation and 
a reduction in the agar concentration Su. Inhibition zone diame-
ters on MHA30P100 and MHA30 supplemented with 150 μg/
mL of protamine (MHA30P150) were similar for all bacterial iso-
lates tested. MHA30P100 was determined as the optimal me-
dium because bacterial growth was hampered at higher prot-
amine concentrations (Supplemental Data Table S1). 
None of the strains grew on MHA30 with ≥300 μg/mL of prot-
amine. However, colistin-susceptible ACB strain, P. aeruginosa 
ATCC 27853, and K. aerogenes strains grew well on MHA30 
supplemented with 200 μg/mL of protamine, whereas colistin-
resistant ACB strains did not. Both P. aeruginosa and ACB strains 
grew well on MHA30P150 (Supplemental Data Table S1). Inhi-
bition zone diameters differed between MHA30P100 and MHA-
30P150 (P <0.001) (Fig. 1). Hence, we decide to adopt MHA-
30P100.
Phase II
We could not discriminate between colistin-susceptible and -re-
sistant strains using commercial MHA. The categorical agree-
ments between MICs determined by BMD were 100% in P. ae-
ruginosa (27/27) and 97% in ACB (32/33), when bacteria were 
grown on MHA30P100 (Table 1). Inhibition zone diameters were 
larger on MHA30P100 than on MHA and MHA30 (Table 2, Fig. 
1). The overall agreement between MICs and MHA30P100 inhi-
bition zone diameters was excellent, with a kappa value of 0.961 
(95% confidential interval (CI), 0.885–1.0, P <0.001). The agree-
ment was 100% for P. aeruginosa and colistin-susceptible ACB 
isolates, whereas it was 94.7% (18/19) for colistin-resistant iso-
lates. A strain of Acinetobacter nosocomialis was susceptible in 
disk diffusion testing using MAH30P100, but resistant in BMD 
testing (Table 2). 
The sensitivity and specificity of colistin disk diffusion testing 
by using MHA30P100 were 94.7% and 100%, respectively (Ta-
ble 3). By analyzing the AUC, we found that MHA30P100 me-
dium allowed the best discrimination between susceptibility and 
resistance in both P. aeruginosa and ACB strains. The AUC of 
MHA30P100 was 0.995 (95% CI, 0.982–1.0) which was higher 
than that for MHA (0.979, 95% CI, 0.939–1.0) and MHA30 
Fig. 1. Change in the colistin inhibition zone diameters with com-
mercial MHA (MHA), commercial MHA with 100 µg/mL protamine 
(MHAP100), MHA with 30% agar (MHA30), MHA30 with 100 μg/
mL protamine (MHA30P100), and MHA30 with 150 μg/mL prot-
amine (MHA30P150). The diffusion of colistin was improved by re-
ducing agar concentration and protamine addition. The difference 
in inhibition zone diameter (mm) around colistin disks between re-

































Table 2. Agreement between MIC and disk diffusion of P. aerugino-




Isolates with colistin 
susceptibility by MIC (N) Total
Susceptible Resistant
MHA30P100 Susceptible 41   1 42
Resistant   0 18 18
Total 41 19 60
Abbreviations: see Table 1. 
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(0.985 95% CI, 0.953-1.0). 
During colistin MIC determination, three ACB strains showed 
discrepancies of >8 μg/mL between MICs using BMD and disk 
diffusion, and were retested twice using glass tubes to rule out 
false resistance finding due to colistin binding to polystyrene 
wells, which has been previously reported [22, 23]. Two strains 
were susceptible to colistin in reference BMD methods, result-
ing in the same category with disk diffusion tests. However, one 
strain remained colistin resistant, which was retested using MHA-
30P100 directly from glass tubes containing 0, 0.5, 1, 2, 4, or 8 
μg/mL of colistin. The bacterial isolate was sub-cultured from 
each tube after MIC measurement and further identified as Aci-
netobacter nosocomialis belonging to ACB. The isolates identi-
fied from the 0.5–1 μg/mL colistin tubes were susceptible to co-
listin, whereas those from the 2–8 μg/mL colistin tubes were re-
sistant (data not shown).  
DISCUSSION 
The main objective of our study was to optimize MHA for im-
proved colistin diffusion. We first modified the agar concentra-
tion, and optimized the medium composition with protamine 
(Fig. 1). When protamine was added to MHA30, colistin diffu-
sion further increased, resulting in larger inhibition zones and a 
clear distinction between resistant and susceptible strains (Fig. 
1). The addition of protamine to MHA30 resulted in the same 
sensitivity and specificity, but facilitated the interpretation of the 
results because the differences in inhibition zone diameters around 
the colistin disks on MHA30P100 were increased (Fig. 1, Table 
1, and Table 3). Although protamine has bacterial growth inhibi-
tion properties [24], bacterial growth was not inhibited at 100 
μg/mL, while colistin diffusion increased; therefore, this concen-
tration was used in further experiments as an optimal concen-
tration [12]. 
Three ACB strains were resistant in BMD tests using polysty-
rene plates, but susceptible in disk diffusion tests using MHA30 
and MHA30 P100. When BMD tests for these three strains were 
repeated using glass tubes, two strains were susceptible to co-
listin in line with the disk diffusion test results. However, one 
strain was resistant. To find the reason, the bacterial isolate was 
sub-cultured from each tube after MIC measurement. Interest-
ingly, the isolates identified from the 0.5–1 μg/mL colistin tubes 
were susceptible, whereas those from the 2–8 μg/mL colistin 
tubes were resistant (data not shown). These findings implicated 
that A. nosocomialis can mutate in vitro after exposure to colis-
tin in BMD, depending on the colistin concentration. 
Colistin diffusion improved in MHA30P100 and therefore, this 
medium can be a useful tool for detecting colistin resistance. 
This simple medium was easy to prepare and allowed identify-
ing colistin-resistant isolates of both P. aeruginosa and ACB with 
94.7% and 100% specificity, respectively. No very major or ma-
jor error were detected in P. aeruginosa as demonstrated by the 
100% agreement between the MICs and inhibition zone diame-
ters on MHA30P100 (Table 1). 
A limitation of MHA30P100 is that it is softer than commercial 
MHA. Therefore, it needs to be handled with caution to avoid 
scratches or crumpling. Some strains of P. aeruginosa became 
more mucoid when grown on 30% agar (data not shown), and 
mucoid colonies preferentially receded to the inhibition zone. In 
this case, a reduced incubation time of 12 hours could have re-
sulted in clear inhibition zones around colistin disks. Further 
evaluation on the effect of incubation time reduction on the per-
formance of this simple disk diffusion test would be required.
In summary, this study demonstrated that reducing the agar 
concentration to 30% of the concentration in commercial MHA 
dramatically improved colistin diffusion and resulted in reliable 
colistin susceptibility testing. This modified MHA is expected to 
be useful in clinical microbiology laboratories for colistin suscep-
tibility testing.
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Table 3. Sensitivity and specificity of cutoff values for each culture 
medium type
Mueller-Hinton  
   agar




MHA 94.7 (74.0-99.9) 95.1 (83.5-99.4) 10
MHA30 94.7 (74.0-99.9) 100 (91.4-100) 12
MHA30P100 94.7 (74.0-99.9) 100 (91.4-100) 13
Abbreviations: see Table 1. 
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